SCHEMBL9890779

SCHEMBL9890779

CNC(=O)Cc1cc(C)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 2/20 0.44
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
POLB P06746 5/20 0.40
GRM2 Q14416 1/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
ANO1 Q5XXA6 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890763 0.85 HDAC7 (0.47) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL9890773 0.84 CNR1 (0.44) ALDH1A1SLC6A4POLBANO1CYP1A2
SCHEMBL9890673 0.84 PTGDR2 (0.52) ALDH1A1MEN1KMT2AKDM4EPTGDR2
SCHEMBL9890778 0.82 GRM2 (0.48) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL9890771 0.82 SHMT1 (0.47) ANO1
SCHEMBL9892693 0.81 PTGDR2 (0.48) SLC6A4PTGDR2ANO1CNR2
SCHEMBL9890728 0.81 FFAR1 (0.46) ALDH1A1KDM4EPTGDR2FFAR1FFAR4
SCHEMBL9890714 0.81 CYP2C19 (0.49) MEN1KMT2ASLC6A4SLC6A3PTGDR2
SCHEMBL9890782 0.79 PSEN1 (0.45) PTGDR2SLC1A3SLC1A2SLC1A1CNR2
SCHEMBL19574651 0.75 NPC1 (0.49) ALDH1A1MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885MEN1 1467/4885KMT2A 78/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885MEN1 1467/4885KMT2A 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.